FDA Brief

Warning letters Drugs

FDA warning letter to

Prime Sports Nutrition

High riskIssued Dec 12, 2025Posted Dec 23, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Prime Sports Nutrition that its website sells SARMs such as LGD-4033 and RAD-140 as unapproved new drugs.

What happened

FDA reviewed the company's website at primesportsnutrition.com in November 2025 and found it offering products marketed as SARMs (selective androgen receptor modulators, lab-made compounds sold to build muscle): LGD-4033 (Ligandrol), RAD-140 (Testolone), MK-677 (Ibutamoren) and S-23. The web pages made drug-type claims, such as building lean muscle, burning fat, boosting testosterone, and relieving Alzheimer's disease and muscle wasting. FDA said no approved application is in effect for these products, and noted safety concerns including life-threatening liver reactions and a possible higher risk of heart attack and stroke.

What FDA found

  1. The SARMs are new drugs that FDA has never approved, so selling them is illegal.

    Section 505(a), FD&C Act (21 U.S.C. 355(a))
  2. Sending these unapproved drugs across state lines is prohibited.

    Section 301(d), FD&C Act (21 U.S.C. 331(d))
  3. Website claims that the products build muscle, burn fat, boost testosterone or treat Alzheimer's disease show they are intended for use as drugs.

    Section 201(g)(1), FD&C Act (21 U.S.C. 321(g)(1)); 21 CFR 201.128
  4. The products are not generally recognized as safe and effective for the uses described in their labeling.

    Section 201(p), FD&C Act (21 U.S.C. 321(p))
  5. Labels calling the products a "research compound" and "not for human consumption" do not cancel out the human-use claims on the website.

What FDA wants

FDA asks the company to reply in writing within 15 working days describing the specific steps taken to correct the violations and prevent them from happening again, with copies of related documents, sent by email to CDER's (Center for Drug Evaluation and Research) Office of Unapproved Drugs and Labeling Compliance. If the work cannot be finished in that time, the company must explain the delay and say when it will be done.

Who should pay attention

  • other supplement and "research chemical" sellers marketing SARMs online
  • e-commerce and marketing teams that write muscle-building or disease claims on product pages
  • brands and platforms listing SARM products for US sale

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk